Synergism of amlodipine and candesartan on blood pressure reduction and organ protection in hypertensive rats

被引:4
作者
Cheng, Yan-Qiong [1 ,2 ]
Tan, Bing-Yi [3 ]
Yu, Xu-Hong [4 ]
Dong, Wen-Zhe [1 ,5 ]
Su, Ding-Feng [1 ]
Zhu, De-Qiu [6 ]
Liu, Ai-Jun [1 ]
机构
[1] Second Mil Med Univ, Dept Pharmacol, Sch Pharm, Shanghai, Peoples R China
[2] Second Mil Med Univ, Dept Urinary Surg, Changhai Hosp, Shanghai, Peoples R China
[3] Shandong Univ, Dept Spinal Surg, Shandong Prov Hosp, Jinan, Shandong, Peoples R China
[4] People Liberat Army 305 Hosp, Dept Pharm, Beijing, Peoples R China
[5] Shanghai Inst Hlth Sci, Dept Pharmacol, Shanghai, Peoples R China
[6] Tongji Univ, Div Pharm, Tongji Hosp, Sch Med, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
amlodipine; candesartan; hypertension; organ protection; synergism; COMBINATION THERAPY; TASK-FORCE; ARTERIAL-HYPERTENSION; DOSE COMBINATION; EUROPEAN-SOCIETY; MANAGEMENT; GUIDELINES; PREVENTION; EFFICACY; TRIPLE;
D O I
10.1111/1440-1681.12901
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study was designed to investigate the possible synergism of amlodipine and candesartan on the reduction of blood pressure (BP) in hypertensive rats. The end organ protection was also observed. In acute experiment, spontaneously hypertensive rats (SHRs) were treated with intragastric administration of amlodipine (0.5, 1, 2, 3mg/kg), candesartan (1, 2, 3, 4, 6, 8mg/kg), and 14 different combinations to find the possible ratio of synergistic interaction. In two kidneys, one clip (2K1C) rats, the effects of amlodipine (1mg/kg), canderastan (2mg/kg) and their combination on BP reduction were also observed. In chronic study, SHRs were treated with amlodipine (1mg/kg), candesartan (2mg/kg), and their combination for 5months. Organ damage evaluation was performed after BP recording. The probability sum test (q test) was used to evaluate the synergistic action. There is a synergistic interaction between amlodipine and candesartan on BP reduction. The optimal dose ratio is 1:2. The synergistic effect was also confirmed by 2K1C hypertensive rats. In chronic study, this combination (1:2) possessed an obvious synergism on the reduction of BP and BP variability (BPV) and protection on end organs. Multiple regression analysis showed that heart and aortic hypertrophy indexes and glomerular damage parameters were positively related to BP and BPV. In conclusion, combination of amlodipine and candesartan exhibited a potent antihypertensive effect and possessed an obvious synergism on BP reduction and organ protection in hypertension. The optimal proportion was 1:2. BP and BPV reduction may both importantly contribute to end organ protection.
引用
收藏
页码:514 / 524
页数:11
相关论文
共 32 条
  • [1] Efficacy of the Combination of Amlodipine and Valsartan in Patients With Hypertension Uncontrolled With Previous Monotherapy: The Exforge in Failure After Single Therapy (EX-FAST) Study
    Allemann, Yves
    Fraile, Belen
    Lambert, Michel
    Barbier, Michaela
    Ferber, Philippe
    Izzo, Joseph L., Jr.
    [J]. JOURNAL OF CLINICAL HYPERTENSION, 2008, 10 (03) : 185 - 194
  • [2] Death hath a thousand doors to let out life ...
    Chandrashekhar, Y
    Narula, J
    [J]. CIRCULATION RESEARCH, 2003, 92 (07) : 710 - 714
  • [3] Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
    Chobanian, AV
    Bakris, GL
    Black, HR
    Cushman, WC
    Green, LA
    Izzo, JL
    Jones, DW
    Materson, BJ
    Oparil, S
    Wright, JT
    Roccella, EJ
    [J]. HYPERTENSION, 2003, 42 (06) : 1206 - 1252
  • [4] Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):: a multicentre randomised controlled trial
    Dahlöf, B
    Sever, PS
    Poulter, NR
    Wedel, H
    Beevers, DG
    Caulfield, M
    Collins, R
    Kjeldsen, SE
    Kristinsson, A
    McInnes, GT
    Mehlsen, J
    Nieminen, M
    O'Brien, E
    Östergren, J
    [J]. LANCET, 2005, 366 (9489) : 895 - 906
  • [5] Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
    Ettehad, Dena
    Emdin, Connor A.
    Kiran, Amit
    Anderson, Simon G.
    Callender, Thomas
    Emberson, Jonathan
    Chalmers, John
    Rodgers, Anthony
    Rahimi, Kazem
    [J]. LANCET, 2016, 387 (10022) : 957 - 967
  • [6] Hypertensive therapy: Part II
    Franco, V
    Oparil, S
    Carretero, OA
    [J]. CIRCULATION, 2004, 109 (25) : 3081 - 3088
  • [7] Goyal J, 2014, J CLIN DIAGN RES, V8, pHC8, DOI 10.7860/JCDR/2014/9352.4500
  • [8] Rationale for Triple-Combination Therapy for Management of High Blood Pressure
    Gradman, Alan H.
    [J]. JOURNAL OF CLINICAL HYPERTENSION, 2010, 12 (11) : 869 - 878
  • [9] Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients
    Jamerson, Kenneth
    Weber, Michael A.
    Bakris, George L.
    Dahlof, Bjorn
    Pitt, Bertram
    Shi, Victor
    Hester, Allen
    Gupte, Jitendra
    Gatlin, Marjorie
    Velazquez, Eric J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (23) : 2417 - 2428
  • [10] The Efficacy and Safety of Triple vs Dual Combination of Angiotensin II Receptor Blocker and Calcium Channel Blocker and Diuretic: A Systematic Review and Meta-Analysis
    Kizilirmak, Pinar
    Berktas, Mehmet
    Uresin, Yagiz
    Yildiz, Okan Bulent
    [J]. JOURNAL OF CLINICAL HYPERTENSION, 2013, 15 (03) : 193 - 200